Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 188 participants.
Also called NCT03254368
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 188 participants
- Sponsor
- Zafgen, Inc.
- Registry
-
NCT03254368 -
U1111-1196-7527
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, New Zealand
- Registry status
- Completed
Technical summary
Registry record NCT03254368. Randomized; quadruple masking; primary purpose treatment. Start 2017-09-12 (actual); primary completion 2018-11-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Overweight and Obesity
- Intervention (Drug)
- ZGN-1061
- Intervention (Drug)
- Placebo
- Lead sponsor
- Zafgen, Inc.
Record details
- Record id
cardio:ct-nct03254368- Content hash
25ecfd10b61a2a0438447b5008464ae84dcd41f2b129deea74203b43f3f76762